STAT3 and neuroblastoma: In this regard, it has been shown that CD114 anti-body therapy and/or targeting its downstream driver STAT3 depletes CSC subpopulation within NB and corresponded with reduced metastatic state, increased chemosensitization and decreased tumor growth[110].